[Skip to Content]
[Skip to Content Landing]
Other Articles
April 1, 1961

New Drugs and Developments in Therapeutics

A Council on Drugs' Digest
Author Affiliations

Scientific data were supplied to the Council by Astra Pharmaceutical Products, Inc. (dextriferron); Cutter Laboratories (plasma protein fraction, human); Endo Laboratories Inc. (oxymorphone hydrochloride); E. Fougera and Company, Inc. (bunamiodyl sodium); and Mead Johnson & Co. (methdilazine hydrochloride).

JAMA. 1961;175(13):1170-1171. doi:10.1001/jama.1961.63040130008012a

Intravenous Iron  Since the withdrawal of iron-dextran complex and the consequent unavailability of a satisfactory preparation of iron for intramuscular injection, intravenously administered hematinics have assumed increased importance. Dextriferron (Astrafer), an iron-carbohydrate complex, is one of the newer of these. It induces a hematological response comparable to that produced by other parenterally given iron compounds: The hemoglobin concentration increases, after a latent period of 3 to 7 days, at a rate inversely proportional to the initial value; maximum reticulocyte response occurs during the first week of therapy and remains high for some time.Although, as pointed out in the Council's statement on iron-dextran complex (JAMA175:388 [Feb. 4] 1961), intravenous administration of iron is accompanied by a higher incidence and greater severity of side-effects than is intramuscular injection, dextriferron seems to be somewhat better tolerated than saccharated iron oxide. Immediate reactions, usually resulting from too rapid administration, include flushing

First Page Preview View Large
First page PDF preview
First page PDF preview